Approximately 50% of HER2-positive breast cancers are HR-positive, i.e. triple-positive breast cancers, while the proportion of HR-negative breast cancers is approximately 30%.ER-positive PR-negative accounts for 15-20%, the existence of ER-negative PR-positive is still controversial. This evidence concerns the gene ERBB2 and breast cancer.